Literature DB >> 25453877

Antegrade pedal approach for recanalizing occlusions in the opposing circulatory pathway of the foot when a retrograde puncture is not possible.

Luis Mariano Palena1, Marco Manzi.   

Abstract

PURPOSE: To describe a novel technical strategy to approach below-the-ankle chronic total occlusions after failed antegrade recanalization in patients who are not candidates for retrograde puncture. TECHNIQUE: After a failure of antegrade recanalization of the tibial and foot vessels, an antegrade pedal access can be performed in the pedal or plantar artery. After crossing the plantar arch and the occlusions in the opposing circulation pathway of the foot, a rendezvous with the antegrade catheter is performed, followed by final angioplasty and hemostasis.
CONCLUSION: An antegrade pedal approach to the opposing circulation in the foot may be considered for below-the-ankle recanalization after standard antegrade recanalization failure in patients who are not candidates for a retrograde puncture.

Entities:  

Keywords:  amputation; angioplasty; antegrade approach; below-the-ankle vessels; below-the-knee angioplasty; chronic total occlusion; critical limb ischemia; diabetes; limb salvage; pedal artery; plantar artery; recanalization; tibial artery

Mesh:

Year:  2014        PMID: 25453877     DOI: 10.1583/14-4801R.1

Source DB:  PubMed          Journal:  J Endovasc Ther        ISSN: 1526-6028            Impact factor:   3.487


  2 in total

1.  Retrograde pedal access with a 20-gauge intravenous cannula after failed antegrade recanalization of a tibialis anterior artery in a diabetic patient: a case report.

Authors:  Yucel Colkesen
Journal:  Diabet Foot Ankle       Date:  2015-08-07

2.  Impact of Pedal Arch Patency on Tissue Loss and Time to Healing in Diabetic Patients with Foot Wounds Undergoing Infrainguinal Endovascular Revascularization.

Authors:  Nicola Troisi; Filippo Turini; Emiliano Chisci; Leonardo Ercolini; Pierfrancesco Frosini; Renzo Lombardi; Francesca Falciani; Cristiana Baggiore; Roberto Anichini; Stefano Michelagnoli
Journal:  Korean J Radiol       Date:  2018-01-02       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.